John Cunningham

Biography
John Cunningham leads an early-stage life science tools company developing next-generation PCR chemistries that enable faster, higher-plex, and more sensitive molecular assays. He previously founded and led RapidBio, a high-throughput molecular diagnostics laboratory that processed more than 300,000 clinical samples during the COVID-19 pandemic and generated over $20M in revenue. Earlier in his career, he served as COO of Functional Fluidics, where he helped build functional biomarker assays for red blood cell health, and spent five years in the University of Michigans Office of Technology Transfer supporting commercialization of academic innovations. His current work focuses on translating novel processor-mediated PCR chemistries into multiplexed assays that expand access to precision oncology and other advanced molecular diagnostics.

---

Talk
PCR Chemistries for High-Plex Precision Diagnostics
Signal Bioscience introduces Processor-Mediated PCR, a novel reagent platform that separates signal generation from amplification. This technology enables tunable signal intensity, allowing 100-plex capabilities on existing digital PCR instruments and significantly enhancing speed and sensitivity for precision diagnostics without requiring new hardware.

Clinical & Research Tools Showcase:
Signal Bioscience
Signal Bioscience is a life science tools company developing novel reagents that extend the functionality of PCR and dPCR instruments by dramatically increasing speed, sensitivity, and multiplexing capabilities. Our proprietary Processor-Mediated PCR platform enables high-performance diagnostics on existing laboratory infrastructure.